Logo

delayed graft function

Quark Kidney Drug Misses Phase II Endpoint, but Phase III Still On Track
Premium

NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week presented data from a Phase II trial of QPI-1002, an siRNA-based drug for the prevention of delayed graft function (DGF) in kidney transplant patients.

Quark Completes Phase II Trial of Delayed Graft Function Drug
Premium

NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week announced that it has completed a Phase II trial of its siRNA-based drug for the prevention of delayed graft function in kidney transplant patients.

As Big Pharma Looks to Niche Diseases, RNAi May Benefit
Premium

While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.

Quark Delayed Graft Function Drug Gets European Orphan Drug Status
Premium

The provisions for the EU orphan designation provide incentives to companies developing orphan drugs, including the potential for up to 10 years of market exclusivity and various fee reductions for certain regulatory activities, Quark said.

Quark Delayed Graft Function Drug Safe in Phase I
Premium

Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.